Acorda Therapeutics, Inc. announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Inbrija (levodopa inhalation powder) from October 5, 2018 to January 5, 2019.
This extension is related to recent submissions Acorda made in response to requests from FDA for additional information on chemistry, manufacturing and controls (CMC). FDA determined that these submissions constitute a major amendment and will take additional time to review.
“We look forward to continuing our constructive dialogue with FDA,” said Ron Cohen, M.D., Acorda’s president and CEO. “We remain committed to bringing Inbrija to approval for people with Parkinson’s who experience OFF periods, which are highly disruptive and in need of new therapeutic options.”
The FDA accepted Acorda’s NDA for Inbrija in February 2018.
About Inbrija (levodopa inhalation powder) and Arcus
Inbrija is a self-administered, orally inhaled levodopa (L-dopa) therapy in development for the treatment of symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.
Inbrija utilizes Acorda’s investigational Arcus platform for inhaled therapeutics. Inbrija was designed to deliver a precise dose of a dry powder formulation of L-dopa through the lung. Oral medication can be associated with variable onset of action, as the medicine is absorbed through the gastrointestinal (digestive) tract before reaching the brain. Inhaled treatments enter the body through the lungs and reach the brain, bypassing the digestive system.
The proprietary name Inbrija has been conditionally accepted by the FDA.
(Source: Acorda Therapeutics, Inc.)
